Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.

Resource Type

CF Research News

Authors

Jain R, Beckett VV, Konstan MW, Accurso FJ, Burns JL, Mayer-Hamblett N, Milla C, VanDevanter DR, Chmiel JF; KB001-A Study Group

References

J Cyst Fibros. 2017 Dec 29. pii: S1569-1993(17)30984-0. doi: 10.1016/j.jcf.2017.12.006

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Date

Friday, December 29, 2017

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [3]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/kb001-novel-anti-inflammatory-found-be-safe-and-well-tolerated

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-17-00377R2_Jain_FINAL_100218.pdf [2] https://www.ncbi.nlm.nih.gov/pubmed/?term=KB001-A%2C%20A%20NOVEL%20ANTI-INFLAMMATORY%2C%20FOUND%20TO%20BE%20SAFE%20AND%20WELL%20TOLERATED%20IN%20CYSTIC%20FIBROSIS%20PATIENTS%20INFECTED%20WITH [3] https://www.ecfs.eu/resource-guideline-type/other-guidelines